|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004587,
umls-concept:C0021083,
umls-concept:C0023866,
umls-concept:C0035020,
umls-concept:C0085957,
umls-concept:C0220901,
umls-concept:C0544452,
umls-concept:C0549193,
umls-concept:C0719214,
umls-concept:C0936012,
umls-concept:C2825406
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2003-4-1
|
|
pubmed:abstractText |
To review prognostic factors identified in clinical trials for remission versus relapse after intravesical adjuvant Bacillus Calmette-Guérin (BCG) immunotherapy for superficial bladder cancer (Ta, T1, and carcinoma in situ).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0302-2838
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
43
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
351-60; discussion 360-1
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12667715-Administration, Intravesical,
pubmed-meshheading:12667715-Adult,
pubmed-meshheading:12667715-Age Distribution,
pubmed-meshheading:12667715-Aged,
pubmed-meshheading:12667715-BCG Vaccine,
pubmed-meshheading:12667715-Carcinoma, Transitional Cell,
pubmed-meshheading:12667715-Female,
pubmed-meshheading:12667715-Humans,
pubmed-meshheading:12667715-Immunotherapy,
pubmed-meshheading:12667715-Incidence,
pubmed-meshheading:12667715-Male,
pubmed-meshheading:12667715-Middle Aged,
pubmed-meshheading:12667715-Neoplasm Recurrence, Local,
pubmed-meshheading:12667715-Probability,
pubmed-meshheading:12667715-Prognosis,
pubmed-meshheading:12667715-Risk Assessment,
pubmed-meshheading:12667715-Sensitivity and Specificity,
pubmed-meshheading:12667715-Sex Distribution,
pubmed-meshheading:12667715-Survival Rate,
pubmed-meshheading:12667715-Treatment Outcome,
pubmed-meshheading:12667715-Urinary Bladder Neoplasms
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature.
|
|
pubmed:affiliation |
Urology Department, Groupe d'Etude des Tumeurs Urologiques (GETU), Hôpital Henri Mondor, 94000, Créteil, France. fabiensaint@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|
